Mortalin (Mot) is a mitochondrial chaperone of the heat shock protein 70 family and it's pro-proliferative and anti-apoptosis functions could be associated with keloid pathogenesis, and blocking of mortalin and its interaction with p53 might be a potential novel target for the treatment of keloid. Therefore, we generated mortalin-specific small hairpin (sh) RNAs (dE1-RGD/GFP/shMot) and introduced into keloid spheroids for examination of its apoptotic and anti-fibrotic effect. On keloid tissues, mortalin expression was higher than adjacent normal tissues and it's protein expressions were activated keloid fibroblasts (KFs). After primary keloid spheroid were transduced with dE1-RGD/GFP/shMot for knockdown of mortalin, expression of type I, III collagen, fibronectin, and elastin was significantly reduced and transforming growth factor-β1, epidermal growth factor receptor (EGFR), Extracellular Signal-Regulated Kinases 1 and 2 (Erk 1/2), and Smad 2/3 complex protein expression were decreased. In addition, increased TUNEL activities and cytochrome C were observed. Further, for examine of mortalin and p53 interaction, we performed immunofluorescence analysis. Knockdown of mortalin relocated p53 to the cell nucleus in primary keloid spheroids by dE1-RGD/GFP/shMot transduction. These results support the utility of knockdown of mortalin to induce apoptosis and reduce ECMs expression in keloid spheroid, which may be highly beneficial in treating keloids.
Keloid scars are locally aggressive, continually grow, and invade the surrounding normal skin, and are caused by increased proliferation and an excess collagen deposition by abnormal fibroblasts. On the basis of these characteristics of keloid, we hypothesize that the pro-proliferative and anti-apoptosis functions of mortalin could be associated with keloid pathogenesis, and targeting mortalin and its interaction with p53 might be a potential novel target for the treatment of keloid. Therefore, in the present study, we investigate the expression of mortalin in keloid and normal tissues, where it protects cell apoptosis by mechanisms involving inactivation of p53 functions. Also, we generated mortalin-specific small hairpin (sh)RNAs (dE1-RGD/GFP/shMot) and introduced into keloid spheroids for examination of its apoptotic and anti-fibrotic effect.
Results
Mortalin expression was increased in keloid tissues compared with adjacent normal tissues. After hematoxylin and eosin (H&E) staining, we observed that keloid tissue had a dense and excessive collagen deposition that extended over the clinical keloid margin into the extra-lesional dermal tissue (Fig. 1a ). To evaluate mortalin protein expression patterns in keloid tissue, immunohistochemical staining was performed (n = 5). Compared to extra-lesional normal tissue ( Fig. 1b & e ), markedly increased mortalin immunoreactivity was noted in central and peripheral keloid region ( Fig. 1c & d) . The increased expression of mortalin was semi-quantitatively measured with MetaMorph ® image analysis software (Fig. 1f) . The results showed that mortalin protein levels were markedly higher in the central and transitional regions of the keloids (optical density; 92446 ± 17322, 99007 ± 19811, respectively) than in normal tissue (optical density; 23005 ± 3969). Protein expression levels of mortalin in keloid tissues were 4.8 times that of normal tissue (**p < 0.01).
Mortalin protein expression was investigated with Western blot analysis (n = 3). As shown in Fig. 2 , mortalin protein levels were 25 times higher in KFs relative to normal dermal tissue, which was further upregulated by 2.3-fold when KFs were activated with transforming growth factor (TGF)-β1 (10 ng/mL), a strong fibrosis inducing factor that plays an important role in the keloid pathophysiology.
Construction of mortalin specific shRNA-expressing adenovirus and their effect on the KFs and keloid spheroids.
On the basis of the results that mortalin expression increased on the keloid tissues, we anticipated that inhibition of mortalin could be applied for keloid or hypertrophic scar treatment. Therefore, we generated mortalin-specific shRNA-expressing adenovirus ( Fig. 3a ) and examined their effect on KFs and keloid spheroids. As shown in Fig. 3b and c, overexpressed mortalin on the cytosolic and extracellular area of KFs ( Fig. 3b ) and primary keloid spheroid ( Fig. 3c ), which were examined by immunofluorescence assay, were extremely knockdown by the treatment of dE1-RGD/GFP/shMot.
Mortalin specific shRNA-expressing adenovirus decreases collagen type I and III, elastin, and fibronectin protein expression in primary human keloid spheroids. Keloid spheroids derived
from active-stage keloid patients (n = 3) were cultured and transduced with either dE1-RGD/GFP/scramble or dEl-RGD/GFP/shMot. The effect of mortalin on expression of major ECM components of keloid was evaluated histologically. Masson's trichrome of keloid sections revealed that collagen deposition was decreased in spheroids transduced with dEl-RGD/GFP/shMot versus scramble virus ( Fig. 4a ). In addition, dense and coarse collagen bundles structure were replaced by thin and shallow collagen bundles. Image analysis of immunohistochemical staining also revealed significantly reduced type I collagen, type III collagen, elastin, and fibronectin in dEl-RGD/ GFP/shMot treated keloid spheroids, by 12%, 43%, 12%, and 18%, respectively, versus scramble virus-transduced spheroids (**p < 0.01 in all cases; Fig. 4b and c). Taken together, these data strongly suggest that expressions of the major ECM components such as collagen type I and III, elastin, and fibronectin are significantly decreased by knockdown of mortalin expression in primary keloid spheroid.
Mortalin specific shRNA-expressing adenovirus elicited decreased expression of TGF-β1, EGFR, and Erk 1/2 on keloid spheroids. We examined that dEl-RGD/GFP/shMot may be decreased expression of TGF-β1 and EGFR on keloid spheroid compared with dE1-RGD/GFP/scramble. Also, to examine the intracellular effect of mortalin specific shRNA-expressing adenovirus, Smad 2/3 complex and Erk 1/2 protein expressions were investigated. As shown in Fig. 4d , significantly decreased expressions of TGF-β1, EGFR, Smad 2/3 complex, and Erk 1/2 protein were observed in mortalin specific shRNA-expressing adenovirus treated keloid spheroids, by 52%, 43%, 11%, and 42%, respectively, versus scramble virus-transduced spheroids (*p < 0.05, **p < 0.01; Fig. 4d and e ). These results demonstrated that knockdown of mortain can attenuate EGF/EGFR signaling pathway and TGF-β1/ Smad pathway, which have an important role in the fibrogenesis. Also, overexpressed mortalin has an important role in keloid pathogenesis and inhibition of mortalin expression could be a therapeutic target on the treatment of keloid or hypertrophic scar.
Knockdown of mortalin decreased PCNA expression and induced apoptosis. Keloid formation
is often considered to be the result of a prolonged cellular proliferation and reduced apoptosis. Therefore, proliferative activities of keloid was examined by a proliferating cell nuclear antigen (PCNA) immunohistochemical staining on keloid tissues (n = 5), resulted that expression of PCNA protein markedly increased in central and transitional keloid region compared to adjacent normal tissue by 3.9 times and 3.2 times, respectively ( Fig. 5a and b ). Next, we examined whether the knockdown of mortalin could decrease cellular proliferation and induce apoptosis in scramble and mortalin specific shRNA-expressing adenovirus-transfected keloid spheroid. Image analysis of immunohistochemical staining revealed significantly reduced PCNA expression in dEl-RGD/GFP/shMot treated keloid spheroids by 29% ( Fig. 5c and d) .
Further, to determine whether reduced mortalin expression induced apoptosis, a TUNEL assay and cytochrome C immune-staining were carried out using the keloid spheroid. As shown in Fig. 5c and d, TUNEL positivities were increased on the dEl-RGD/GFP/shMot-treated keloid spheroids, and expression of cytochrome the KFs (Fig. 6a ) and keloid tissues (n = 5) ( Fig. 6b-c) were confirmed, and the localization of p53 was found in the cytoplasm as well as the nucleus, but most of them expressed in the cytoplasm. The cytoplasmic accumulation of p53 was especially noticeable on the keloid tissues. We next investigated whether mortalin would cause inactivation of p53 function by cytoplasmic sequestration. If so, apoptosis caused by mortalin knockdown would be expected to involve nuclear translocation of the p53 and induce an apoptosis by reactivation of p53. To test this hypothesis, we performed immunofluorescence analysis on keloid spheroid (n = 3). Transduction of dEl-RGD/GFP/shMot led to significant accumulation of p53 in the nucleus. As shown in Fig. 6d , colocalizations of p53 and mortalin in the cytosol were investigated on the untreated keloid spheroid. After mortalin specific shRNA-expressing adenovirus was treated on the keloid spheroids, mortalin expressions were knockdown and they was exhibited intense nuclear staining for p53, suggesting the nuclear translocation. In line with these findings, a time-dependent increase in nuclear p53 level was confirmed by western blot analysis in dEl-RGD/ shMot-treated primary keloid fibroblast ( Supplementary Fig. S3 ). In contrast, no nuclear p53 level was increased in scrambled shRNA-expressing Ad-treated cells.
Disscusion
Keloids are fibro-proliferative skin lesions that are characterized by excessive accumulation of ECM componentsmainly collagens-and invasion into normal peripheral regions. Increased cell proliferation, accounting for the progressive and hypertrophic nature of keloids, correlates with a lower rate of apoptosis 5, 7, 9 , which may play a role in the process of pathological scarring. Therefore, apart from the researches keloid pathogenesis caused by increased proliferation and an excess collagen deposition by fibroblasts, the understanding of the mechanisms by which keloids escape from apoptosis could be beneficial in the development of novel therapeutic strategies.
Our data showed that mortalin and tumor suppressor protein p53 expression were increased on the keloid tissues compared with adjacent normal tissues, especially on the cytosol. In addition, mortalin expression significantly increased after TGF-β1 (10 ng/mL) treatment on keloid fibroblasts. Mortalin (mot-2/mthsp70/PBP74/ GRP75) is an essential protein belonging to the Hsp70 family of chaperones, and its overexpression confers proliferation-growth advantages to cells 15, 16, 18, 20, 21 . Mortalin is primarily localized in the mitochondria but is also found in the endoplasmic reticulum, plasma membrane, and cytoplasmic vesicle 29 . It is also found as a secreted protein and detected in the extra-cellular space 29 . It protects cells from senescence and apoptosis and is overexpressed in cancer cells, but yet few report identified its role in fibrotic disease such as keloid. Therefore, we think that overexpressed mortalin in keloid tissue compared to the adjacent normal tissue could be an important role in fibrogenesis. In light of this, we generated mortalin-specific small hairpin (sh)RNAs (dE1-RGD/GFP/shMot) and introduced into keloid spheroids for examination of its apoptotic and anti-fibrotic effect. After the transduction of dE1-RGD/GFP/shMot, expressions of the major ECM components are significantly decreased in primary keloid spheroid, and knockdown of mortain can attenuate EGF/EGFR signaling pathway and TGF-β1/Smad pathway, which have a role in the fibrogenesis. The number of studies revealed that extracellular Hsp70 (Hsp 72) promotes TLR4 signaling leading to TGF-β1 activation [30] [31] [32] [33] , and Hsp47 is a collagen-specific molecular chaperone that plays a critical role in normal procollagen biosynthesis in mammals 34, 35 . However, the functional rule of mortalin for the fibrogenesis remains unclear. Therefore, additional researches will be needed.
The fibrotic process is maintained by the inhibition of apoptosis in myofibroblasts, which produce an excess of ECM, thereby causing keloid or hypertrophic scar. A number of nuclear proteins have been shown to redistribute to the cytosol and mitochondria at the onset of apoptosis. Among these, the tumor-suppressor protein p53 is a short lived nuclear phosphoprotein, which has transcription-dependent effects that involves induction of pro-apoptotic genes 14, 36, 37 and overexpression of p53 [7] [8] [9] had been found in keloids. In line with these reports, primary patient keloid fibroblast samples used in this study expressed wild type p53 ( Supplementary Fig. S1 ).
The effects of overexpressed mortalin such as malignant transformation 38 , life span extension 15 , and attenuation of differentiation 39 has been attributed, at least in part, to transcriptional inactivation of p53. There is well known that mortalin (amino-terminus region) was found to bind to the carboxy-terminus region of p53, resulting in cytoplasmic retention and transcriptional inactivation of p53 16, [18] [19] [20] [21] . Also, it localizes in the nucleus, inactivates p53-mediated apoptosis 28 . On the basis of theses knowledge, we blocked the cytosolic mortalin by dE1-RGD/ GFP/shMot, and expected it to discharge p53 from mortalin-p53 complex resulting in its functional activation. As shown in our data, we examined that knockdown of mortalin induced nuclear translocation of the p53 and decrease cell proliferation. Also, apoptotic activity, cytochrome C release, and TUNEL positivities were increased on the dE1-RGD/GFP/shMot treated keloid spheroid.
On our researches, we found that functional roles of dE1-RGD/GFP/shMot such as anti-proliferative function, antifibrosis, and increase apoptotic activity could be expected to be of great advantage in keloid or hypertrophic scars therapeutics. Despite this role, the potential therapeutic use of shMot-expressing adenovirus possesses limitations, such as a transient effect, which is not desirable to chronically persistent keloids, acute inflammatory responses, and the innate immune response. Exhaustive research efforts has prompted the development of novel SCIeNTIfIC RepoRts | 7: 12957 | DOI:10.1038/s41598-017-13485-y strategies to overcome these limitations 40 . Therefore, we think that further refinement studies will be needed for more efficient and safe gene transfer in patients.
Materials and Method
Human dermal fibroblast, keloid tissue, and keloid-derived fibroblast cells. Human normal dermal fibroblasts (HDFs) and keloid fibroblasts (KFs) were obtained from the ATCC (American Type Culture Collection, Manassas, VA). After obtaining informed consent according to a protocol approved by the Yonsei University College of Medicine Institutional Review Board, keloid tissues and normal abdominal skin tissues were obtained for fibroblast culture, histologic, and immunohistochemical analysis with excision. Keloid fibroblasts were obtained from both the central dermal layer of keloids (Supplementary Table 1 ). All experiments involving humans were performed in adherence to the Helsinki Guidelines. Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL).
Immunohistochemistry (IHC) for mortalin, p53, and PCNA. Formaldehyde-fixed tissues were transferred to a paraffin-embedded block, sectioned at 4-μm thicknesses. After tissue deparaffinization and rehydration, endogenous peroxidase activity was blocked by 10-min incubation at room temperature with absolute methanol containing 1% hydrogen peroxide. The tissue sections were incubated with a primary antibody against mouse anti-mortalin monoclonal antibody (C1-3), rabbit anti-p53 (sc-6243; Santa Cruz biotechnology, Santa Cruz, CA), and mouse anti-PCNA (M0879; DAKO, Carpinteria, CA) at 4 °C overnight. After incubation with the secondary antibody (Super Sensitive ™ Polymer-HRP IHC, BioGenex) for 1 h at room temperature, the bound complexes were visualized by incubating tissue sections with 0.05% diaminobenzidine and 0.003% hydrogen peroxide. The sections were counterstained with Harris hematoxylin and then dehydrated and mounted. Mortalin, p53, and PCNA protein levels were semi-quantitatively analyzed using MetaMorph ® image analysis software (Universal Image Corp., Buckinghamshire, UK). Results are expressed as mean optical density of six different digital images per sample.
Generating shMot-expressing adenoviral vectors. A replication-incompetent Ad expressing shMot
(dE1-RGD/GFP/shMot; Ad-shMot) and control Ad (dE1-RGD/GFP/scramble; Ad-scramble) were used in this study (Fig. 3 ). Both replication-incompetent Ads possess RGD, a tripeptide composed of L-arginine, glycine, and L-aspartic acid that recognizes subtypes of integrins, in their fiber to improve the transduction to keloid fibroblasts in comparison to wild-type Ad by providing an alternative viral entry pathway into keloid fibroblasts 41, 42 .
To generate an Ad expressing GFP and shMot or scramble at the E1 and E3 regions, respectively, pdE1-RGD/ GFP 43 was linearized by SpeI digestion and co-transformed into Escherichia coli BJ5183 with the XmnI-digested pSP72-E3/CMV-shMot or -scramble E3 shuttle vector 44 for homologous recombination, generating a pdE1-RGD/ GFP/shMot or /scramble adenoviral vector. The propagation, purification, and titration of Ad were performed as described previously 45,46 . Preparation and adenoviral transduction of keloid spheroids. Keloid tissues were obtained from active-stage keloid patients (n = 5). Keloid spheroids were prepared by dissecting keloid central dermal tissue into 2-mm diameter pieces with sterile 21-gauge needles. Explants were plated onto HydroCell ® 24 Multi-well plates (Nunc, Rochester, NY) after which they were cultured for 4 h in IMDM (Isocove's modified Dulbecco's medium, Gibco BRL) supplemented with 5% fetal bovine serum, 10 mM l −1 insulin and 1 mM l −1 hydrocortisone. Each of the Ads (dE1-RGD/GFP/shMot and dE1-RGD/GFP/scramble) at 1 × 10 10 VP were added into the plates containing keloid spheroid, and incubated at 37 °C in 5% CO 2 incubator for 3 days. The transduced keloid spheroids were then fixed with 10% formalin, paraffin-embedded, and cut into 5-μm-thick sections.
Histology and immunohistochemistry. Representative Western blot analysis. KFs were lysed in a solution containing 50 mM Tris-HCl (pH 7.6), 1% Nonidet P-40 (NP-40), 150 mM NaCl, 0.1 mM zinc acetate, and protease inhibitors. Protein concentration was determined by the Lowry method (Bio-Rad, Hercules, CA), and 30 μg of each sample was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins on the gel were electrotransferred to polyvinylidene fluoride membrane, incubated with the primary mouse anti-mortalin monoclonal antibody (C1-3) and rabbit anti-β-actin antibody (Sigma, St Louis, MO), and then secondarily incubated with the HRP (horseradish peroxidase)-conjugated secondary antibody (#7074 or 7076; Cell Signaling Technology). The expression patterns were revealed using the ECL detection kit (sc-2004; Santa Cruz Biotechnology), and the expression levels of mortalin was developed using enhanced chemiluminescence (Amersham Pharmacia Biotech, Uppsala, Sweden). Mortalin protein was semi-quantitatively analyzed using ImageJ software (National Institutes of Health, Bethesda, MD).
Immunofluorescence assay. Keloid tissue sections (n = 4) were deparaffinized, rehydrated, blocked with 5% goat serum, and incubated with mouse anti-mortalin monoclonal antibody (C1-3) or rabbit anti-p53 (sc-6243; Santa Cruz biotechnology) primary antibody overnight at 4 °C. Day after incubation, sections were washed with phosphate-buffered saline (PBS) and incubated with Alexa Flour 488-conjugated goat anti-mouse IgG (A11001; Invitrogen, Carlsbad, CA) or Alexa Flour 633-conjugated goat anti-rabbit IgG (A21070; Invitrogen) secondary antibody for 60 min at room temperature. Tissues were mounted on slides using Vectashield ® mounting medium containing the nuclear stain DAPI (Vector Laboratories, Burlingame, CA), and viewed by confocal microscopy (LSM700, Olympus, Center Valley, PA).
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) assay. The apoptotic spheroid population was assessed by TUNEL assay as described previously (Gene Ther, 2008. 15(9): p. 635-51). The apoptotic cells were visually identified in five randomly selected fields and photographed at a magnification of x100 and x400. The expression level of apoptotic spheroid was semi-quantitatively analyzed using MetaMorph ® image analysis software. Results are expressed as the mean optical density for five different digital images.
Statistics.
Results are expressed as the mean ± standard error of the mean (SEM). Data were analyzed by a repeated-measures one-way ANOVA. Two sets of independent sample data were compared using a paired t-test; p-values < 0.05 was considered indicative of statistically significant differences.
